Pharmafile Logo
Pharmafocus logo
Advanced Search

Research and Development

Showing 15 posts of 9578 posts found.

tablet_production_2

Further positive trial results boost Amgen and UCB’s romosozumab

March 21, 2016 Research and Development, Sales and Marketing Amgen, Romosozumab, UCB, clinical trial, osteoporosis, phase 3, phase III, regulatory approval

Amgen (NASDAQ:AMGN) and UCB (EBR:UCB) have announced positive top line results for romosozumab in men with osteoporosis in the Phase …
News
celgene

Celgene’s ozanimod meets endpoints in Phase II ulcerative colitis trials

March 21, 2016 Research and Development, Sales and Marketing Celgene

Celgene International Sàrl, a Celgene subsidiary, has announced additional data of exploratory endpoints from a Phase II trial of ozanimod …
News

US FDA rejects application for Eagle Pharma’s blood thinner; shares plunge

March 21, 2016 Research and Development, Sales and Marketing Eagle Pharmaceuticals, Kangio, US FDA, blood thinner

Shares in Eagle Pharmaceuticals (Nasdaq: EGRX) closed down almost 19% Friday after the US Food and Drug Administration rejected the …
News
pfizer-building-logo1web

Pfizer’s JAK inhibitor meets endpoints in Phase III ulcerative colitis trials

March 21, 2016 Research and Development, Sales and Marketing JAK inhibitor, Pfizer, ecco, endpoint, octave, tofacitinib, ulcerative colitis

Pfizer (NYSE:PFE) has announced that investigational JAK inhibitor – oral tofacitinib – met the primary and secondary endpoints in two …
News
janssen_stairs_1

J&J says psoriasis drug Stelara shows positive results in trials for Crohn’s disease

March 18, 2016 Medical Communications, Research and Development Crohn’s disease, J&J, JJ, Stelara, crohn's disease

Johnson & Johnson (NYSE: JNJ) on Friday said a second late-stage trial of its psoriasis drug Stelara (ustekinumab) has shown effectiveness …
News
abraxane0058

Wales approve pancreatic cancer drug for use despite NICE rejection in England

March 18, 2016 Medical Communications, Research and Development Abraxane, Celgene, England, NHS, NICE, Wales, approval

Celgene (Nasdaq: CELG) has announced that Abraxane, in combination with gemcitabine, will continue to be an available treatment option for …
News

Study data supports switch to Celltrion’s Remicade biosimilar

March 18, 2016 Research and Development

Celltrion and distribution partner Mundipharma have presented study data supporting switching irritable bowel disease (IBD) patients from Remicade to biosimilar …
News
clinical_trial-web

OncoMed initiates Phase Ib immuno-oncology combination clinical trial

March 18, 2016 Medical Communications, Research and Development Merck, OncoMed, clinical trial, demcizumab, immuno-oncology, immuno-oncology combination, pembrolizumab, phase ib

OncoMed (NASDAQ: OMED) has announced the beginning of its Phase Ib clinical trial to investigate if the combination of demcizumab …
News
zydelig_gilead

Gilead cancer boss departs after safety concerns halt Zydelig trials

March 18, 2016 Medical Communications, Research and Development Gilead Sciences, zydelig

In the wake of the halting of six clinical trials of its blood cancer drug Zydelig due to safety concerns, …
News

Kite Pharma, Roche to co-develop two new treatments for non-hodgkin lymphoma

March 18, 2016 Medical Communications, Research and Development Gentech, Roche, kite pharma, non-Hodgkin lymphoma

Kite Pharma (Nasdaq: KITE) said it will collaborate with Swiss drug major Roche (SIX: ROG) to evaluate the safety and efficacy …
News
breckenridge_pharma

FDA approves Breckenridge’s generic of Pfizer’s anti-epilepsy drug

March 18, 2016 Research and Development, Sales and Marketing FDA, Neurontin, Pfizer, anti-epilepsy, approval, breckenridge, gabapentin, tris pharma

Breckenridge Pharmaceutical Inc. has announced that their generic of Pfizer’s anti-epilepsy drug Neurontin (gabapentin) has been approved by the US …
News
msd

Merck & Co says study shows significantly higher persistence for its arthritis drug Simponi

March 17, 2016 Research and Development, Sales and Marketing Merck & Co, drug trial, research, rheumatoid arthritis

US pharma giant Merck & Co (NYSE: MRK) said its rheumatoid arthritis drug showed significantly higher persistence compared with other drugs …
News
shutterstock_95714119

Vitae Pharma soars on positive mid-stage trial results for psoriasis drug

March 17, 2016 Business Services, Research and Development, Sales and Marketing Vitae Pharmaceuticals, drug trial, psoriasis, research

Shares in Vitae Pharmaceuticals (Nasdaq: VTAE) nearly doubled in pre-market trading Thursday after the company reported mid-stage trials of its psoriasis …
News
bayercross3

FDA approves Bayer haemophilia A drug Kovaltry

March 17, 2016 Research and Development, Sales and Marketing Bayer, FDA, approval, drug, drug approval, haemophilia, haemophilia a, kovaltry, viii compound

Bayer (ETR:BAYN) has received approval from the US Food and Drug Administration (FDA) for Kovaltry (octocog alfa), an unmodified, full-length …
News
chugai_pharmaceutical

Chugai receive orphan drug status for autoimmune disease treatment

March 17, 2016 Manufacturing and Production, Medical Communications, Research and Development chuagi, systemic scleroderma, tocilizumab

Chugai Pharmaceutical Co. (TYO: 4519) has received a notification of orphan drug designation, from the Japanese minister of health, labour …
News
The Gateway to Local Adoption Series

Latest content

Just – Evotec given Gates Foundation grant to increase global biotherapeutics access

January 8, 2026

Johnson & Johnson submits robotic surgical system for De Novo classification

January 8, 2026

EA Pharma announces phase 3 trial for new schizophrenia treatment in Japan

January 7, 2026

Eleva appoints Erich Rajkovic as Chief Business Officer

January 7, 2026

MedPharm announces US FDA inspection of North Carolina manufacturing facility

January 6, 2026